Please visit answersincme.com/DRN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastroenterology discusses emerging small molecule therapies in the treatment of moderate-to-severe Crohn’s disease. Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using emerging selective Janus kinase (JAK) inhibitors and sphingosine 1–phosphate (S1P) receptor modulators in Crohn’s disease; Describe evidence from late-stage clinical trials on the use of small molecule therapies in individuals with moderate-to-severe Crohn’s disease; and Outline patient-centered strategies for optimizing treatment with small molecule therapies in moderate-to-severe Crohn’s disease.

Please visit answersincme.com/CUA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in rheumatology discusses treatment options for non-radiographic axial spondyloarthritis (nr-axSpA). Upon completion of this activity, participants should be better able to: Recognize guideline-recommended treatment options used to reduce the burden of non-radiographic axial spondyloarthritis (nr-axSpA) on patients; Describe the clinical impact of approved and late-stage emerging agents for the treatment of nr-axSpA; and Outline clinical considerations for the role of approved and late-stage emerging agents in the treatment landscape of nr-axSpA.

Please visit answersincme.com/FKQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Dr. Anne O’Donnell, an expert in pulmonology, discusses the role of diagnostic imaging in the diagnosis of non–cystic fibrosis bronchiectasis (NCFB). Upon completion of this activity, participants should be better able to: Recognize the clinical impact of early diagnosis of non–cystic fibrosis bronchiectasis (NCFB); Identify NCFB based on diagnostic imaging; and Describe the clinical profiles of novel and emerging neutrophil-targeted therapies for NCFB.

Please visit answersincme.com/YWV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses treatment of children with uncontrolled asthma using biologic therapies. Upon completion of this activity, participants should be better able to: Recognize pediatric patients with inadequately controlled moderate-to-severe asthma who may benefit from treatment intensification with a biologic; Review the clinical profiles of current biologics used in the management of moderate-to-severe asthma in children; and Outline evidence-based strategies to optimize outcomes for pediatric patients with moderate-to-severe asthma who require biologics.

Please visit answersincme.com/BWT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatric asthma discusses how to identify children with uncontrolled asthma who could benefit from an add-on biologic. Upon completion of this activity, participants should be better able to: Recognize pediatric patients with inadequately controlled moderate-to-severe asthma who may benefit from treatment with add-on biologic therapy; Review the clinical impact of biologics approved for the treatment of pediatric patients with moderate-to-severe asthma; and Outline patient-centered strategies to enhance outcomes for pediatric patients with inadequately controlled moderate-to-severe asthma.

Please visit answersincme.com/DUR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an allergist and immunologist discusses individualized treatment for children with moderate-to-severe asthma. Upon completion of this activity, participants should be better able to: Identify pediatric patients with inadequately controlled moderate-to-severe asthma who may benefit from add-on biologic therapy; Describe the clinical profiles of available biologics for the management of inadequately controlled moderate-to-severe asthma in pediatric patients; and Outline strategies to provide individualized, evidence-based treatment for inadequately controlled moderate-to-severe asthma in pediatric patients.

Please visit answersincme.com/GZT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the latest data in systemic treatments for children with moderate-to-severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Recognize the rationale for treatment intensification with novel systemic agents when managing children with moderate-to-severe atopic dermatitis (AD); Review the latest clinical data informing the current and future use of novel systemic agents in children with moderate-to-severe AD; and Identify opportunities for shared decision-making to improve the care of children with moderate-to-severe AD.

Please visit answersincme.com/JUK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in immunology discusses the burden of respiratory syncytial virus (RSV) in older adults and the clinical impact of late-stage emerging RSV vaccines. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for vaccines to prevent respiratory syncytial virus (RSV) in older adults; Identify factors contributing to poor RSV outcomes in older adults; and Describe the clinical significance of available data for late-stage investigational RSV vaccines in older adults.

Please visit answersincme.com/KAG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert on immunization discusses the mechanisms of COVID-19 vaccines, the clinical impact of viral vector–based vaccines and how to improve communication with patients regarding vaccine uptake.Upon completion of this activity, participants should be better able to: Recognize the mechanism of action of available COVID-19 vaccines; Evaluate the clinical impact of available viral vector–based COVID-19 vaccines; and Apply patient-centered counseling strategies to enhance communication with patients to improve COVID-19 vaccine acceptance.

Please visit answersincme.com/TAC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in infectious diseases discusses the early identification and treatment of patients with COVID-19 who are at a higher risk of progression to severe illness. Upon completion of this activity, participants should be better able to: Identify nonhospitalized patients with COVID-19 who have risk factors for progression to severe illness; Describe national guideline recommendations for the therapeutic management of nonhospitalized patients with COVID-19 who are at risk for progression to severe illness; and Outline a personalized management approach to enhance outcomes for nonhospitalized patients who are diagnosed with COVID-19 and are at risk for progression to severe illness.